Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04595578
Other study ID # 2017-10-166
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2017
Est. completion date March 31, 2018

Study information

Verified date October 2020
Source Samsung Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The present study investigated the efficacy and safety of combination treatment of repetitive transcranial magnetic stimulation (rTMS) and physical therapy (PT) in patients with cerebellar variant of multiple system atrophy (MSA-C) and spinocerebellar ataxia.


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date March 31, 2018
Est. primary completion date March 31, 2018
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: 1. The patients with probable MSA-C and spinocerebellar ataxia (SCA) 2. cerebellar ataxia as main clinical presenting feature and able to walk independently without walking devices 3. aged over 20 4. presence of cerebellar atrophy proven by brain MRI. Exclusion Criteria: 1. secondary cerebellar ataxia 2. peripheral neuropathy, radiculopathy, or decreased visual acuity that can cause peripheral ataxia 3. musculoskeletal disease affecting gait or balance 4. other neurologic symptoms, including symptomatic parkinsonism (two or more rigidity and/or bradykinesia scores in one limb by Unified Parkinson's disease Rating Scale part 3) or spasticity (20) 5. psychiatric symptoms requiring medication or with cognitive decline (Mini-mental state examination [MMSE] < 20) 6. taking any sedative medications or anti-parkinsonian medications such as benzodiazepine, levodopa or dopamine agonist 7. history of seizure or metallic brain implants; (8) cardiopulmonary diseases causing dyspnea during exercise.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Cerebellar repetitive transcranial magnetic stimulation
rTMS was delivered on the scalp for over 2 cm under the inion, which is the scalp over the cerebellum area, using a double-cone coil connected to a Magstim Rapid2® stimulator with two Booster Modules (Magstim, Spring Gardens, Wales, UK) in accordance with safety recommendations. Stimulation was delivered to the cerebellum at 10 Hz with 90% of the mean resting motor threshold intensity for 5 seconds at 55 second intervals to deliver 1000 pulses in 20 minutes. Immediately after rTMS, the combination treatment group received balance and gait training by a physical therapist for 30 minutes/day and underwent aerobic exercise using a stationary bicycle at moderate intensity (12 to 14 rating of perceived exertion) for 30 minutes/day and 5 days/week for two weeks. In the control group, no participants received physical therapy or rTMS for two weeks.

Locations

Country Name City State
Korea, Republic of Samsung Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary International Cooperative Ataxia Rating Scale (ICARS) The scale is scored out of 100 with 19 items and 4 subscales of postural and gait disturbances, limb ataxia, dysarthria, and oculomotor disorders. Higher scores indicate higher levels of impairment. The change of ICARS score between baseline (T0) and immediately after (T1) treatment
Secondary Change from temporospatial parameters of gait Gait parameters measured by GAITRite system The clinical scales were evaluated by blinded raters at baseline (T0) and immediately after (T1), 4 weeks after (T2), and 12 weeks (T3) after intervention.
Secondary Change from posturography Posturography measured by Pedoscan system The clinical scales were evaluated by blinded raters at baseline (T0) and immediately after (T1), 4 weeks after (T2), and 12 weeks (T3) after intervention.
Secondary Change from Mini-Mental State Examination (MMSE) Measurement of cognitive function The clinical scales were evaluated by blinded raters at baseline (T0) and immediately after (T1), 4 weeks after (T2), and 12 weeks (T3) after intervention.
Secondary Change from Beck depression inventory (BDI) Measurement of symptoms of depression The clinical scales were evaluated by blinded raters at baseline (T0) and immediately after (T1), 4 weeks after (T2), and 12 weeks (T3) after intervention.
Secondary Change from Barthel Index for Activities of Daily Living Measurement of activities of daily living The clinical scales were evaluated by blinded raters at baseline (T0) and immediately after (T1), 4 weeks after (T2), and 12 weeks (T3) after intervention.
Secondary Change from International Cooperative Ataxia Rating Scale (ICARS) The scale is scored out of 100 with 19 items and 4 subscales of postural and gait disturbances, limb ataxia, dysarthria, and oculomotor disorders. Higher scores indicate higher levels of impairment. The clinical scales were evaluated by blinded raters at baseline (T0) and 4 weeks after (T2), and 12 weeks (T3) after intervention.
See also
  Status Clinical Trial Phase
Recruiting NCT05973019 - rTMS Improves Functions in Spinocerebellar Ataxia N/A
Completed NCT04837027 - Effect of Training on Brain Volume in Ataxia N/A
Completed NCT03745248 - Aerobic Exercise, Balance Training, and Ataxia N/A
Completed NCT05951010 - Cerebellar Transcranial Direct Current Stimulation in Spinocerebellar Ataxia 38 N/A
Completed NCT01037777 - RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7
Completed NCT00136630 - Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations
Completed NCT03687190 - Could Tai-chi Help Maintain Balance of Spinocerebellar Ataxia Patients N/A
Active, not recruiting NCT03701399 - Troriluzole in Adult Subjects With Spinocerebellar Ataxia Phase 3
Completed NCT05436262 - Using Real-time fMRI Neurofeedback and Motor Imagery to Enhance Motor Timing and Precision in Cerebellar Ataxia N/A
Recruiting NCT04231487 - Using Wearable and Mobile Data to Diagnose and Monitor Movement Disorders
Withdrawn NCT04301284 - Study of CAD-1883 for Spinocerebellar Ataxia Phase 2
Not yet recruiting NCT06397274 - Stemchymal® for Polyglutamine Spinocerebellar Ataxia Phase 2
Not yet recruiting NCT06177626 - Impact of Exercise on Eyeblink Conditioning in Spinocerebellar Ataxias N/A
Recruiting NCT04529252 - Investigating the Genetic and Phenotypic Presentation of Ataxia and Nucleotide Repeat Diseases
Completed NCT05621200 - Transcranial Alternating Current Stimulation (tACS) in Patients With Ataxia N/A
Completed NCT03701776 - Ataxia and Exercise Disease Using MRI and Gait Analysis N/A
Completed NCT03120013 - Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia N/A
Active, not recruiting NCT03408080 - Open Pilot Trial of BHV-4157 Phase 3
Active, not recruiting NCT02960893 - Trial in Adult Subjects With Spinocerebellar Ataxia Phase 2/Phase 3
Completed NCT04153110 - Cerebello-Spinal tDCS as Rehabilitative Intervention in Neurodegenerative Ataxia N/A